This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
April 2010
·
20 Reads
·
26 Citations
Nature Reviews Drug Discovery
Biologics currently dominate the market for disease-modifying drugs for rheumatoid arthritis, but companies are betting that there is room for next-generation oral drugs that target protein kinases.
... We previously predicted many novel protein kinase targets for mebendazole [17]. Kinase inhibition is a sought after therapeutic strategy for rheumatoid arthritis, especially as non-biologic treatment alternatives and for methotrexate-resistant cases [65][66][67]. Inhibitors of spleen tyrosine kinase (Syk) and Janus kinases (Jaks) have shown short-term efficacy, but other kinases inhibitors with good long-term effect profiles may also exist. Other kinases implicated in RA pathogenesis include aurora kinases [68] and cyclindependent kinases (CDKs) [69]. ...
April 2010
Nature Reviews Drug Discovery
